Patients with focal segmental glomerulosclerosis (FSGS) are at increased risk of progression to kidney failure within 10 years of diagnosis. Studies have shown an association between lowering proteinuria across a range of thresholds and a reduction in the risk for kidney failure.
The ongoing phase 3 DUPLEX trial was designed to assess the efficacy and safety of sparsentan in patients with FSGS. During a session at the 63rd European Renal Association Congress in Glasgow, Scotland, Sian Griffin, MBBC, PhD, and colleagues presented long-term open-label extension (OLE) data from the trial.
Participants in the DUPLEX study who received sparsentan in the double-blind period and continued in the OLE, as well as those who switched from irbesartan (IRB) and initiated sparsentan in the double-blind period and remained on sparsentan in the OLE, maintained durable reductions in proteinuria and achieved clinically meaningful low proteinuria thresholds over time, including complete remission.
During the OLE, patients who remained on sparsentan maintained durable reductions in proteinuria and continued to achieve clinically meaningful low thresholds of proteinuria. At any time across the double-blind or OLE period, 37.5% achieved complete remission (CR), defined as urine protein-to-creatinine ratio (UPCR) less than 0.3 g/g, and 87.5% achieved partial remission (UPCR <1.5 g/g). Participants who switched from IRB to sparsentan in the OLE experienced rapid and sustained reductions in proteinuria, 28.9% achieved CR at any time across the double-blind or OLE period, and 74.6% achieved partial remission.
Sparsentan was generally well tolerated during the OLE follow-up period, with a safety profile consistent with earlier findings and low rates of treatment discontinuation related to treatment-emergent adverse events.
Jula Inrig, MD, chief medical officer of Travere Therapeutics, said in a press release, “These long-term open-label extension data continue to reinforce the meaningful and sustained impact [sparsentan] can have for people living with FSGS without nephrotic syndrome. Patients experienced clinically meaningful reductions in proteinuria after initiating [sparsentan], whether treatment began during the double-blind period or after transition from [IRB] in the open-label extension. The continued response observed over approximately 5 years, including 3 years in the open-label extension, further validates the benefit of [sparsentan] and adds to a growing body of evidence supporting its role as foundational care in FSGS.”